Breaking News Instant updates and real-time market news.

PFE

Pfizer

$43.13

-0.65 (-1.48%)

10:30
10/15/18
10/15
10:30
10/15/18
10:30

Pfizer call option buyers as shares slip

Pfizer call option buyers as shares slip. The stock off 75c to $43.03 and Nov 45s trade from 40 to 43c, including 8.8K for 40c when bid-ask was 39 to 42c. 12.2K trade against 5K open interest and the market is 41 to 43c. Earnings 10/30.

  • 17

    Oct

  • 19

    Oct

  • 19

    Oct

  • 22

    Oct

  • 30

    Oct

  • 07

    Nov

PFE Pfizer
$43.13

-0.65 (-1.48%)

10/08/18
GSCO
10/08/18
NO CHANGE
Target $36
GSCO
Sell
Ionis' Tegsedi to face commercial headwinds, says Goldman Sachs
After the FDA approved Ionis (IONS) and affiliate Akcea Therapeutics' (AKCA) Tegsedi for adult polyneuropathy of hereditary transthyretin-mediated amyloidosis, but with a black box warning, Goldman Sachs analyst Salveen Richter said he believes the drug faces commercial headwinds. He cites the underlying safety profile and requirement for consistent monitoring as well as the recent launch of Alnylam's (ALNY) Onpattro and expected launch of Pfizer's (PFE) tafamidis in the first half of 2019. Richter keeps a Sell rating on Ionis shares with a price target of $36.
10/02/18
PIPR
10/02/18
NO CHANGE
Target $100
PIPR
Neutral
AbbVie scripts for Humira relatively weak in Q3, says Piper Jaffray
Piper Jaffray analyst Christopher Raymond says new survey data from dermatologists and gastroenterologists indicate AbbVie's (ABBV) Humira is losing share faster in psoriasis and inflammatory bowel disease than in rheumatoid arthritis. In that management has called out psoriasis as a key driver of growth, the survey feedback may help explain Humira's relatively weak script trends for Q3, Raymond tells investors in a research note. The analyst believes dermatologists are embracing newer biologics such as Johnson & Johnson's (JNJ) Tremfya while gastroenterologists favor Takeda's Entyvio and increasingly Pfizer's (PFE) Xeljanz. Raymond remains cautious on shares of AbbVie ahead of European biosimilar erosion he expects to start this month. He keeps a Neutral rating on the stock with a $100 price target.
10/01/18
JPMS
10/01/18
NO CHANGE
Target $46
JPMS
Overweight
Pfizer price target raised to $46 from $42 at JPMorgan
JPMorgan analyst Chris Schott raised his price target for Pfizer to $46 on a revisit of the company's story. The analyst sees a "meaningful shift" in the Pfizer narrative away from potential acquisitions to the company's organic growth prospects post the Lyrica patent expiration in 2019. While he expects the company's growth will slow in 2019/2020, he sees a "distinct re-acceleration" of sales and earnings growth for Pfizer in the 2021-2025 period. Schott believes shares of Pfizer can further re-rate if the Street gains further confidence in its "sustained topline growth and capital deployment opportunities." The analyst keeps an Overweight rating on the shares.
09/18/18
JPMS
09/18/18
NO CHANGE
Target $81
JPMS
Overweight
Market evolving favorably for Ascendis into Phase III results, says JPMorgan
JPMorgan analyst Jessica Fye believes the long-acting growth hormone deficiency competitive landscape is evolving favorably for Ascendis Pharma heading into the Phase III results for the company's TransCon growth hormone in Q1 of 2019. The past 12-24 months has brought emerging clinical issues for all three of the key long-acting competitors, Fye tells investors in a research note. These range from the failure of Versartis (VSAR) at the most extreme, to the missed pivotal trial in adults for Pfizer (PFE) and Opko (OPK), to results that may raise questions around efficacy for Novo (NVO) in adults, Fye contends. The analyst believes these create opportunity for Ascendis, assuming the company is successful in Phase III. She continues to have high conviction in the success of the Phase III trial and keeps an Overweight rating on Ascendis Pharma with an $81 price target.

TODAY'S FREE FLY STORIES

SDC

SmileDirectClub

$10.33

-0.77 (-6.94%)

11:32
10/14/19
10/14
11:32
10/14/19
11:32
Recommendations
SmileDirectClub analyst commentary  »

SmileDirectClub may have…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

INTC

Intel

$51.65

-0.41 (-0.79%)

11:28
10/14/19
10/14
11:28
10/14/19
11:28
Periodicals
Intel may skip 10nm for desktop CPUs, Wccftech reports »

Intel is planning to skip…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 20

    Nov

BKNG

Booking Holdings

$1,985.99

11.08 (0.56%)

, FB

Facebook

$183.97

-0.23 (-0.12%)

11:25
10/14/19
10/14
11:25
10/14/19
11:25
Periodicals
Booking Holdings no longer supporting Facebook's Libra cryptocurrency, CNBC says »

CNBC Now tweeted…

BKNG

Booking Holdings

$1,985.99

11.08 (0.56%)

FB

Facebook

$183.97

-0.23 (-0.12%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Oct

  • 30

    Oct

M

Macy's

$15.17

-0.56 (-3.56%)

11:25
10/14/19
10/14
11:25
10/14/19
11:25
Options
Macy's call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

CARA

Cara Therapeutics

$19.13

0.29 (1.54%)

11:22
10/14/19
10/14
11:22
10/14/19
11:22
Recommendations
Cara Therapeutics analyst commentary  »

Stifel still optimistic…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AZUL

Azul

$37.10

0.25 (0.68%)

, UAL

United Airlines

$86.50

-0.68 (-0.78%)

11:20
10/14/19
10/14
11:20
10/14/19
11:20
Periodicals
Azul in talks to join United, Copa, Avianca partnership, Reuters reports »

Brazilian airline Azul…

AZUL

Azul

$37.10

0.25 (0.68%)

UAL

United Airlines

$86.50

-0.68 (-0.78%)

CPA

Copa Holdings

$98.68

-0.67 (-0.67%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

  • 12

    Nov

  • 14

    Nov

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

11:17
10/14/19
10/14
11:17
10/14/19
11:17
Technical Analysis
NASDAQ market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

11:16
10/14/19
10/14
11:16
10/14/19
11:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KEM

Kemet

$20.96

0.305 (1.48%)

11:15
10/14/19
10/14
11:15
10/14/19
11:15
Options
Kemet put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

I

Intelsat

$24.59

0.26 (1.07%)

11:05
10/14/19
10/14
11:05
10/14/19
11:05
Options
Intelsat call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DE

Deere

$169.81

-1.16 (-0.68%)

11:03
10/14/19
10/14
11:03
10/14/19
11:03
Hot Stocks
Deere to acquire Unimil, terms not disclosed »

Deere & Company has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

SDC

SmileDirectClub

$10.48

-0.62 (-5.59%)

11:01
10/14/19
10/14
11:01
10/14/19
11:01
Hot Stocks
Breaking Hot Stocks news story on SmileDirectClub »

SmileDirectClub says…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

SDC

SmileDirectClub

$10.44

-0.66 (-5.95%)

11:00
10/14/19
10/14
11:00
10/14/19
11:00
Hot Stocks
SmileDirectClub says CA assembly bill 1519 creates 'unnecessary hurdles' »

SmileDirectClub issued a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

TPR

Tapestry

$24.69

-1.28 (-4.93%)

10:55
10/14/19
10/14
10:55
10/14/19
10:55
Options
Tapestry put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 07

    Nov

10:55
10/14/19
10/14
10:55
10/14/19
10:55
Conference/Events
Evercore REITs analyst to hold a luncheon »

REITs Analyst Sakwa holds…

PUBGY

Publicis

$0.00

(0.00%)

, DIS

Disney

$129.71

-0.37 (-0.28%)

10:54
10/14/19
10/14
10:54
10/14/19
10:54
Periodicals
Disney splitting $3B media business with Publicis, Omnicom, Campaign reports »

Disney (DIS) is set to…

PUBGY

Publicis

$0.00

(0.00%)

DIS

Disney

$129.71

-0.37 (-0.28%)

OMC

Omnicom

$74.82

0.17 (0.23%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Oct

  • 24

    Oct

  • 24

    Oct

  • 07

    Nov

ALXN

Alexion

$99.63

0.37 (0.37%)

10:45
10/14/19
10/14
10:45
10/14/19
10:45
Options
Alexion call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 23

    Oct

WDC

Western Digital

$59.26

0.9 (1.54%)

, AAPL

Apple

$237.68

1.47 (0.62%)

10:39
10/14/19
10/14
10:39
10/14/19
10:39
On The Fly
Western Digital rises as analyst says buy on rising flash prices »

Shares of Western Digital…

WDC

Western Digital

$59.26

0.9 (1.54%)

AAPL

Apple

$237.68

1.47 (0.62%)

STX

Seagate

$53.60

-0.2 (-0.37%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Oct

  • 01

    Nov

  • 04

    Nov

  • 14

    Nov

  • 19

    Nov

  • 20

    Nov

HUM

Humana

$264.13

-2.2 (-0.83%)

10:34
10/14/19
10/14
10:34
10/14/19
10:34
Hot Stocks
Humana among five MA plans selected for Florida Medicare retirees »

Humana (HUM), which…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Nov

  • 13

    Nov

EHTH

eHealth

$54.37

-1.61 (-2.88%)

10:29
10/14/19
10/14
10:29
10/14/19
10:29
Recommendations
eHealth analyst commentary  »

eHealth churn concerns…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

BHC

Bausch Health

$20.50

-0.12 (-0.58%)

10:25
10/14/19
10/14
10:25
10/14/19
10:25
Options
Bausch Health call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Nov

GNUS

Genius Brands

$0.83

0.06 (7.79%)

10:25
10/14/19
10/14
10:25
10/14/19
10:25
Conference/Events
Genius Brands to host business news update conference call »

Conference call to be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Oct

10:25
10/14/19
10/14
10:25
10/14/19
10:25
Conference/Events
UBS technology analyst to hold an analyst/industry conference call »

Technology Analyst…

SDC

SmileDirectClub

$10.56

-0.54 (-4.86%)

10:20
10/14/19
10/14
10:20
10/14/19
10:20
Recommendations
SmileDirectClub analyst commentary  »

SmileDirectClub may or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

10:17
10/14/19
10/14
10:17
10/14/19
10:17
Technical Analysis
NASDAQ market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.